How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,381 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Extrakt aus Cannabis sativa (Spastik aufgrund von multipler Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 26 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG (...) to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-27 Extract from Cannabis sativa (spasticity due to multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-27 Version 1.0 Extract from Cannabis sativa (spasticity due to multiple sclerosis) 26 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

42. Varicella Zoster Virus glycoprotein E antigen (Shingrix) - Herpes Zoster

Varicella Zoster Virus glycoprotein E antigen (Shingrix) - Herpes Zoster 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 25 January 2018 EMA/88588/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Shingrix International non-proprietary name: herpes zoster vaccine (recombinant, adjuvanted) Procedure (...) Mediated Immunity CPV Continued Process Verification CSR Clinical Study Report DOPC Dioleoyl Phosphatidylcholine ELISA Enzyme-Linked Immunosorbent Assay EMA European Medicines Agency, EU EOS End of Study EPC End-of-Production Cell bank EU European Union FB Final Bulk FC Final Container FDA Food and Drug Administration, US FLU-D-QIV GSK’s unadjuvanted quadrivalent seasonal influenza vaccine FP Finished Product GCP Good Clinical Practice gE Glycoprotein E GM Geometric Mean GMP Good Manufacturing Practice

2018 European Medicines Agency - EPARs

43. Responsible use of high-risk medical devices: the example of 3D printed medical devices

” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How to refer to this document? Vinck I, Vijverman A, Vollebregt E, Broeckx N, Wouters K, Piët M, Bacic N, Vlayen J, Thiry N, Neyt M.Responsible use of high-risk medical devices: the example of 3D printed medical devices. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2018. KCE Reports . D/2018/10.273/03. This document is available on the website of the Belgian Health Care (...) ) Participation in scientific or experimental research as an initiator, principal investigator or researcher: Philip Tack (IWT Project ‘Roadmap’ about medical 3D Printing (part Health economy: PHD traject), Jan Schrooten (Projects KU Leuven – generative medicine / VLAIO feasibility assessment Antheron BV.B.A.), Stefaan Nijs (3D modelling in shoulder althea prof. (UZ Leuven – KU Leuven)) A grant, fees or funds for a member of staff or another form of compensation for the execution of research described above

2018 Belgian Health Care Knowledge Centre

44. Methodology for Creating Expert Consensus Decision Pathways

; Michael E. DeBakey Medical Center—Director, Cardiac Care Unit Melissa Magwire Content Reviewer—Expert Consensus Decision Pathway Writing Committees Shawnee Mission Endocrinology & Diabetes—Clinical Supervisor Catherine M. Otto Content Reviewer—Expert Consensus Decision Pathway Writing Committees J. Ward Kennedy-Hamilton Endowed Chair in Cardiology—Editor-in-Chief, Heart; University of Washington—Professor of Medicine Sarah A. Spinler Content Reviewer—Roundtable Planning Committee Philadelphia College (...) None None None Dharam J. Kumbhani UT Southwestern Medical Center— Assistant Professor, Interventional Cardiology, Department of Internal Medicine n ACC* None None None None None Thomas M. Maddox BJC HealthCare/Washington University School of Medicine—Executive Director, Healthcare Innovation Lab; Washington University School of Medicine—Professor of Medicine (Cardiology) None None None None n BJC Healthcare/ Washington University School of Medicine* None Joseph E. Marine Johns Hopkins School

2019 American College of Cardiology

45. Translation of a C. difficile Treatment Clinical Pathway Into Machine-Readable Clinical Decision Support Artifacts Prototyped for Electronic Health Record Integration

of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted (...) technology may not be able to fully access information in this report. For assistance contact EPC@ahrq.hhs.gov. Suggested citation: Michel J, Flores E, Mull N, Tsou AY. Translation of a Clinical Pathway for C. Difficile Treatment Into a Machine-Readable Clinical Decision Support Artifact Prototyped for Electronic Health Record Integration. Methods Research Report. (Prepared by the ECRI Institute –Penn Medicine Evidence-based Practice Center under Contract No. 290-2015-00005- I.) AHRQ Publication No. 20

2019 Effective Health Care Program (AHRQ)

46. MammaPrint test for personalised management of adjuvant chemotherapy decisions in early breast cancer

patients KCE Report 298 ¦ SCIENTIFIC REPORT a http://www.eunethta.eu/ 1 INTRODUCTION AND SCOPE Gene expression profiling (GEP) tests aim to improve decision-making related to adjuvant chemotherapy treatment for women with early breast cancer. In 2014, KCE performed a rapid HTA on this topic 1 and concluded that there were no data on the clinical utility of such tests and that an update of the review should be performed as soon as RCT results on such aspect became available. Following the publication (...) , decisions on when the use of adjuvant chemotherapy is appropriate and necessary to minimise the risk of recurrence and improve the prognosis of ER+, HER2- early breast cancer patients with up to 3 affected lymph nodes (i.e. the subject of interest of this review), remain in some cases challenging. d http://www.predict.nhs.uk/ e http://www.pmidcalc.org 8 MammaPrint ® test in adjuvant chemotherapy decisions for early breast cancer patients KCE Report 298 3 MAMMAPRINT® IN EARLY BREAST CANCER 3.1 MammaPrint

2018 Belgian Health Care Knowledge Centre

47. External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114.

the small size of the highly selective sample of patients included in the evidence base (as compared to the large burden of disease that migraine creates), the conclusions about effectiveness and the positive safety profile appear to be inflated. The target population of e-TNS are not only patients refractory to medication, but mainly drug responsive patients, which makes replacing the use of medication a main objective of e-TNS. That is why larger controlled trials with best practice interventions (...) External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114. External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine - Repository of AIHTA GmbH English | Browse - - - External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine Stanak, M. and Wolf, S. and Jagoš, H. (2018): External stimulation

2018 Austrian Institute of Health Technology Assessment

48. Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative E Full Text available with Trip Pro

Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative E The prospective observational ROADMAP study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management) demonstrated that ambulatory advanced heart failure patients selected for left ventricular (...) assist device (LVAD) were more likely to be alive at 1 year on original therapy with ≥75-m improvement in 6-minute walk distance compared with patients assigned to optimal medical management. Whether baseline health-related quality of life (hrQoL) resulted in a heterogeneity of this treatment benefit is unknown.Patient-reported hrQoL was assessed with EuroQol questionnaire and visual analogue scale (VAS). We aimed to identify predictors of event-free survival and survival with acceptable hrQoL (VAS

2017 Circulation. Heart failure

49. E?learning of evidence?based health care (EBHC) to increase EBHC competencies in healthcare professionals: a systematic review Full Text available with Trip Pro

| +27733798411 Centre for Evidence‐based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa Centre for Vaccines and Immunology (CVI), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa Centre for the Development of Best Practices in Health (CDBPH), Yaounde, Cameroon Francie van Zijl drive, Parow, Cape Town, 7500 South Africa Dr E-mail address: +49‐89‐440077494 Institute for Medical Informatics, Biometry and Epidemiology, Ludwig‐Maximilians (...) , Parow, Cape Town, 7500 South Africa Dr E-mail address: +49‐89‐440077494 Institute for Medical Informatics, Biometry and Epidemiology, Ludwig‐Maximilians‐University, Marchioninistr. 15, Munich, 81377 Germany Prof E-mail address: +27‐21‐938 9001 Centre for Evidence‐based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl drive, Parow, Cape Town, 7500 South Africa First published: 02 March 2017 Citations: Linked article: . Give access Share full text access

2017 Campbell Collaboration

50. Intrapartum care for women with existing medical conditions or obstetric complications and their babies

://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated April 2019 Page 6 of 96Recommendations Recommendations People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including (...) on consent and mental capacity), and safeguarding. Supporting women to make decisions about their care is particularly important during the intrapartum period. Healthcare professionals should ensure that women have the information they need to make decisions and to give consent in line with General Medical Council (GMC) guidance and the 2015 Montgomery ruling. 1.1 Information for women with existing medical conditions 1.1.1 Clarify with women with existing medical conditions whether and how they would

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

51. Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer

Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer Nov2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged EUnetHTA Joint Action 3 WP4 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment MammaPrint ® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer Project ID (...) , patients can be divided into low- and high-risk groups, which in turn supports clinical decision- making for adjuvant treatment. MammaPrint ® has been prospectively validated for use in early- stage breast cancer patients with tumours 5% or HR 5% at =3 years follow-up and a GRADE B survival improvement as between 3% and 5%. In the case that mature survival data is not available, GRADE A clinical benefit is assigned when DFS improvements are found in which the HR is 70 19 (0.7) 11 (1.9) 16 (1.0) 10 (0.6

2018 EUnetHTA

52. Kidney Pre-biopsy medication: Desmopressin acetate

SAY? Kidney Disease Outcomes Quality Initiative: No recommendation. UK Renal Association: No recommendation. Canadian Society of Nephrology: No recommendation. European Best Practice Guidelines: No recommendation. International Guidelines: No recommendation. SUGGESTIONS FOR FUTURE RESEARCH Randomised controlled trials comparing desmopressin against placebo are required to inform clinical decision making. Such trials should include patients with varying degrees of acute and chronic renal impairment (...) . Microsurgery. 2013;33(1):79-80. 21. Marques R, Rogers J, Chavin K, et al., editors. Does treatment of cadaveric organ donors with desmopressin increase the likelihood of pancreas graft thrombosis? Results of a preliminary study. Transplant Proc; 2004: Elsevier. 22. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. The Lancet. 1999;354(9194):1940-7

2020 KHA-CARI Guidelines

53. Effectiveness of mental health electronic medical records

with clinical workflows, and difficulties navigating the software. On the other hand, positive outcomes included more timely, complete, legible and easily accessed patient records to support clinical decision-making, especially for screening and assessment tools, and care planning. The most convincing benefits were associated with implementation of e-prescribing for medication safety and in the systematic documentation of risk factors for suicide that prompted development of management plans for suicide (...) of whether they use EMRs or paper systems. Indeed, research regarding the effects of EMRs on saving time for clinicians shows mixed results and suggests that time savings are likely dependent on the EMRs design and usability. For example, a 2018 pre- and post- implementation study of the same EMRs in two sites found that the time spent on documentation increased in one site and decreased in another. E- prescribing systems have been linked with improved medication safety, especially in contexts where high

2020 Sax Institute Evidence Check

54. Guidance for maternal medicine in the evolving coronavirus (COVID-19) pandemic

risk factors present40 Royal College of Obstetricians and Gynaecologists, 10-18 Union Street, London, SE1 1SZ T: +44 (0) 20 7772 6200 E: covid-19@rcog.org.uk W: rcog.org.uk Registered Charity No. 213280 @RCObsGyn @rcobsgyn @RCObsGyn DISCLAIMER: The Royal College of Obstetricians and Gynaecologists (RCOG) has produced this guidance as an aid to good clinical practice and clinical decision-making. This guidance is based on the best evidence available at the time of writing, and the guidance (...) for adaptation of maternal medicine services to safely reduce face-to-face contact during the evolving coronavirus pandemic, for example by offering virtual consultations where appropriate, ensuring women are seen in one-stop clinics that cover all medical and obstetric needs in the same visit, avoiding unnecessary hospital admissions and offering new innovations, such as home monitoring of blood pressure, where it is safe to do so. • Specific advice for healthcare professionals caring for pregnant women

2020 Royal College of Obstetricians and Gynaecologists

55. Management of adult cardiac arrest in the COVID-19 era. Interim guidelines from the Australasian College for Emergency Medicine

in the COVID-19 era. This is a preprint version of an article submitted for publication in the Medical Journal of Australia. Changes may be made before final publication. Click for the PDF version. Suggested citation: Craig S, Cubitt M, Jaison A, et al. Management of adult cardiac arrest in the COVID-19 era. Interim guidelines from the Australasian College for Emergency Medicine. Med J Aust 2020; https://www.mja.com.au/journal/2020/management-adult-cardiac-arrest-covid-19-era-interim-guidelines (...) Management of adult cardiac arrest in the COVID-19 era. Interim guidelines from the Australasian College for Emergency Medicine Management of adult cardiac arrest in the COVID-19 era. Interim guidelines from the Australasian College for Emergency Medicine | The Medical Journal of Australia search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual

2020 MJA Clinical Guidelines

56. Cancer and the Health Effects of Cannabis and Cannabinoids: An update of the systematic review by the National Academies of Sciences, Engineering, and Medicine (2017) Consensus Study Report

or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Evans W, Durocher-Allen L, Daeninck P, Hammond D, Lofters A, Selby P, Slaven M. Cancer and the Health Effects of Cannabis and Cannabinoids: An update of the National Academies of Sciences, Engineering, and Medicine (2016). Toronto (ON): Ontario Health (Cancer Care Ontario); 2020, June 29. Program in Evidence-Based Care Evidence Summary No.: 23-2, available (...) patients, the benefits must also be weighed against potential harms from adverse events. Patients with pre-existing mental illness may have more adverse effects from cannabis-based medications. More research is needed comparing cannabis-based medicine with current standard analgesics used to manage cancer pain and studies need to make clear the type(s) of cancer pain being evaluated and the adverse events experienced by cancer patients. Conclusion: There is limited evidence that cannabis-based

2020 Cancer Care Ontario

57. A resource for developing an evidence synthesis report for policy-making

A resource for developing an evidence synthesis report for policy-making Leena Eklund Karlsson | Ryoko Takahashi HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 50 A resource for developing an evidence synthesis report for policy-makingThe Health Evidence Network HEN – the Health Evidence Network – is an information service for public health decision-makers in the WHO European Region, in action since 2003 and initiated and coordinated by the WHO Regional Office for Europe under the umbrella (...) of the European Health Information Initiative (a multipartner network coordinating all health information activities in the European Region). HEN supports public health decision-makers to use the best available evidence in their own decision-making and aims to ensure links between evidence, health policies and improvements in public health. The HEN synthesis report series provides summaries of what is known about the policy issue, the gaps in the evidence and the areas of debate. Based on the synthesized

2017 WHO Health Evidence Network

58. Moving Toward a Recovery-Oriented System of Care: A Resource for Service Providers and Decision Makers

Moving Toward a Recovery-Oriented System of Care: A Resource for Service Providers and Decision Makers www.ccsa.ca • www.ccdus.ca Moving Toward a Recovery- Oriented System of Care A Resource for Service Providers and Decision Makers September 2017 Moving Toward a Recovery- Oriented System of Care A Resource for Service Providers and Decision Makers Suggested citation: Canadian Centre on Substance Use and Addiction (2017). Moving Toward a Recovery-Oriented System of Care: A Resource for Service (...) Providers and Decision Makers. Ottawa, Ont.: Author. © Canadian Centre on Substance Use and Addiction, 2017. CCSA, 500–75 Albert Street Ottawa, ON K1P 5E7 Tel.: 613-235-4048 Email: recovery@ccsa.ca Production of this document has been made possible through a financial contribution from Health Canada. The views expressed herein do not necessarily represent the views of Health Canada. This document can also be downloaded as a PDF at www.ccsa.ca Ce document est également disponible en français sous le

2017 Canadian Centre on Substance Abuse

59. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer Full Text available with Trip Pro

/JCO.2017.74.0472 Journal of Clinical Oncology - published online before print July 10, 2017 PMID: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update x Ian Krop , x Nofisat Ismaila , x Fabrice Andre , x Robert C. Bast , x William Barlow , x Deborah E. Collyar , x M. Elizabeth Hammond , x Nicole M. Kuderer , x Minetta C. Liu , x Robert G. Mennel , x (...) in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD. I.K. and V.S. contributed equally as Expert Panel co-chairs. Abstract Section: Purpose This focused update

2017 American Society of Clinical Oncology Guidelines

60. Does advance care planning alter management decisions made by healthcare professionals?

/AdvanceCarePlanning.pdf Although there is a significant body of literature informing the development and implementation of advance care planning processes, the impact of completed advance care plans on the decision making of healthcare professionals at the time of a medical event is less clear. Evidence for the impact of advance care planning programmes on the quality of care provided is required to underpin funding and delivery of integrated advance care planning across care settings. The purpose of this rapid (...) in the ACP, there is no direct correlation with preferences expressed in the ACP and outcomes, so the specific impact of stated patient preferences on outcome is unclear Cohen- Mansfield et al 2008 Study Setting & Design – A single care home, USA; Retrospective observational study. Study Objective To ascertain the role that advance directives (ADs) play in actual decision making in nursing homes at the time of a medical event. Participants 6 physicians and 3 nurses 64 patients with an AD in place

2017 Palliative Care Evidence Review Service (PaCERS)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>